BioNTech partners with MediLink, pays $70M upfront to go up against Daiichi Sankyo in HER3

First, HER2. Now, HER3. That’s the plan of attack for BioNTech in its apparent bid to follow in the footsteps of antibody-drug conjugate leader Daiichi Sankyo.

After licensing a HER2-targeting ADC from DualityBio in April and taking the treatment candidate into Phase III this fall, BioNTech is now teaming up…
Click here to view original post